Ovasave, an Abu Dhabi-based digital health startup focused on fertility and hormonal care, has raised $1.2m in pre-seed funding, a sign of growing investor appetite for women’s health innovation across the Gulf.
The funding round was led by PlusVC, Annex Investments, and New York-based venture studio 25 Madison. It also drew support from strategic angel investors and family offices across the UAE and Saudi Arabia, reflecting a widening pool of capital being deployed into early-stage femtech ventures.
Backed by Abu Dhabi’s Hub71 ecosystem and registered with the Department of Health – Abu Dhabi, Ovasave is positioning itself as a pioneer in a segment long underserved across the region.
The company plans to use the funding to accelerate its expansion across the GCC, build new corporate partnerships, and roll out the next phase of its mobile platform, which will offer menstrual cycle tracking, symptom monitoring, AI-guided treatment protocols, and access to care.
Ovasave aiming to fill gap when it comes women’s healthcare in the region
“There is a critical need for timely intervention in women’s health, particularly around fertility and hormonal health,” said Torkia Mahloul, co-founder and CEO of Ovasave. “This funding marks a crucial step in our mission to disrupt women’s health and expand access across the region.”
Majd Abu Zant, co-founder of Ovasave, added that Abu Dhabi’s regulatory support and proximity to decision-makers have been central to their early momentum. “It’s the right environment to build and scale high-impact ventures. From here, we are expanding into Saudi Arabia and the wider MENA region,” he said.
The raise comes amid a push by Gulf governments to diversify healthcare offerings and advance gender equality through national policy. In the UAE, reforms in healthcare, technology, and women’s rights have created a fertile ground for emerging FemTech players to gain traction.
Femtech, once considered a niche sub-sector, is increasingly drawing investor interest. A recent report by FemTech Analytics projects the MENA femtech market will reach $3.8bn by 2031, growing at a compound annual rate of 15 percent.
Startups like Ovasave are hoping to ride that wave by addressing long-standing taboos and gaps in care, particularly in fertility and hormonal health.
The startup is now preparing to launch in Saudi Arabia later this summer, as part of a broader three-year regional growth strategy. By combining AI-powered tools with direct access to care, Ovasave aims to move women’s health from reactive to proactive – a shift that investors are starting to bet on.
